These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Author: Lin TC, Yang CY, Yang YH, Lin SJ.
    Journal: J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731.
    Abstract:
    CONTEXT: The evidence for relative effectiveness of osteoporosis drugs in secondary prevention of nonvertebral fractures was unclear and could not be extrapolated to the Asian population. OBJECTIVE: The objective of the study was to compare the relative effectiveness of different classes of osteoporosis drugs in secondary prevention of nonvertebral fractures in Taiwanese women. DESIGN: This was a retrospective cohort study from 2003 to 2007, with up to 6 years of follow-up. SETTING: The study included enrollees in Taiwan National Health Insurance. PATIENTS: Patients older than 50 years, with vertebral/hip fracture and were new to osteoporosis therapy, were recruited. INTERVENTION: Patients were classified into the alendronate, calcitonin, or raloxifene group, according to their exposure after follow-up. MAIN OUTCOME MEASURE: The primary outcome of our study was the risk of incident nonvertebral fracture (hip, humerus, or radius fractures). A multivariate Cox proportional hazard model adjusted for fracture risk factors was used to compare the relative fracture risk among three treatment groups under on-treatment scenarios. Propensity score-matched hazard ratios were examined, and interactions between fracture incidence and patients' compliance were investigated as well. RESULTS: There were 19 840, 9534, and 25 483 patients in the alendronate, raloxifene, and calcitonin groups, respectively. The fracture rates were highest in calcitonin recipients (4.57 per 100 person-years), followed by raloxifene and alendronate. Results from Cox analyses showed raloxifene (hazard ratio 1.47; 95% confidence interval 1.29-1.67) and calcitonin (hazard ratio 1.51; 95% confidence interval 1.29-1.75) had higher nonvertebral fracture risks as compared with alendronate. The risk differences were more pronounced in compliant patients. CONCLUSION: We found alendronate users had the lowest secondary nonvertebral fracture risk, as compared with raloxifene and calcitonin users. Consistent results were found in a series of sensitivity analyses.
    [Abstract] [Full Text] [Related] [New Search]